Portage Biotech Stock Net Asset
| PRTG Stock | USD 4.62 0.10 2.21% |
Portage Biotech fundamentals help investors to digest information that contributes to Portage Biotech's financial success or failures. It also enables traders to predict the movement of Portage Stock. The fundamental analysis module provides a way to measure Portage Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Portage Biotech stock.
Portage | Net Asset |
Portage Biotech Company Net Asset Analysis
Portage Biotech's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Portage Biotech Net Asset | 7.78 M |
Most of Portage Biotech's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Portage Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Portage Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Portage Biotech is extremely important. It helps to project a fair market value of Portage Stock properly, considering its historical fundamentals such as Net Asset. Since Portage Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Portage Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Portage Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Portage Total Assets
Total Assets |
|
Based on the recorded statements, Portage Biotech has a Net Asset of 7.78 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Portage Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Portage Biotech's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Portage Biotech could also be used in its relative valuation, which is a method of valuing Portage Biotech by comparing valuation metrics of similar companies.Portage Biotech is currently under evaluation in net asset category among its peers.
Portage Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Portage Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Portage Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Portage Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Portage Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Portage Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Portage Biotech's value.| Shares | Princeton Global Asset Management Llc | 2024-09-30 | 8.0 | The Toronto-dominion Bank | 2024-06-30 | 7.0 | Qube Research & Technologies | 2024-06-30 | 4.0 | Brown Brothers Harriman & Co | 2024-06-30 | 0.0 | Royal Bank Of Canada | 2024-06-30 | 0.0 | Sigma Planning Corp | 2024-06-30 | 0.0 | Beacon Investment Advisory Services, Inc. | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 1.5 M | Lakeview Capital Partners, Llc | 2024-06-30 | 213.4 K |
Portage Fundamentals
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 1.55 M | ||||
| Shares Outstanding | 1.05 M | ||||
| Shares Owned By Insiders | 29.80 % | ||||
| Shares Owned By Institutions | 13.97 % | ||||
| Number Of Shares Shorted | 14.52 K | ||||
| Price To Book | 1.93 X | ||||
| EBITDA | (18.2 M) | ||||
| Net Income | (75.34 M) | ||||
| Cash And Equivalents | 21.18 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 47 K | ||||
| Current Ratio | 11.73 X | ||||
| Book Value Per Share | 2.39 X | ||||
| Cash Flow From Operations | (14.3 M) | ||||
| Short Ratio | 0.16 X | ||||
| Earnings Per Share | 24.40 X | ||||
| Target Price | 140.0 | ||||
| Beta | 99.48 | ||||
| Market Capitalization | 4.85 M | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (239.32 M) | ||||
| Working Capital | 4.82 M | ||||
| Net Asset | 7.78 M |
About Portage Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Portage Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Portage Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Portage Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Portage Biotech is a strong investment it is important to analyze Portage Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Portage Biotech's future performance. For an informed investment choice regarding Portage Stock, refer to the following important reports:Check out Portage Biotech Piotroski F Score and Portage Biotech Altman Z Score analysis. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 24.4 | Return On Assets (0.19) | Return On Equity (1.91) |
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.